Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?
Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dompmartin A, d'Incan M, Maubec E, Grange F, Dereure O, Prey S, Barete S, Wetterwald M, Fraitag S, Petrella T. Dalle S, et al. Among authors: wetterwald m. Br J Dermatol. 2010 Jan;162(1):74-9. doi: 10.1111/j.1365-2133.2009.09373.x. Epub 2009 Jun 22. Br J Dermatol. 2010. PMID: 19689477
Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients.
Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dereure O, Wetterwald M, d'Incan M, Grange F, Cornillon J, Tertian G, Maubec E, Saiag P, Barete S, Templier I, Aubin F, Dalle S. Julia F, et al. Among authors: wetterwald m. Br J Dermatol. 2013 Sep;169(3):579-86. doi: 10.1111/bjd.12412. Br J Dermatol. 2013. PMID: 23646868
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.
Chretien ML, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, Karlin L, Roussel M, Stoppa AM, Guilhot F, Lamy T, Garderet L, Pegourie B, Dib M, Sebban C, Lenain P, Brechignac S, Royer B, Wetterwald M, Legros L, Orsini-Piocelle F, Voillat L, Delbrel X, Caillot D, Macro M, Facon T, Attal M, Moreau P, Avet-Loiseau H, Corre J. Chretien ML, et al. Among authors: wetterwald m. Haematologica. 2014 Jul;99(7):1236-8. doi: 10.3324/haematol.2013.098608. Epub 2014 Apr 11. Haematologica. 2014. PMID: 24727820 Free PMC article.
Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy.
Hebbar M, Kaplan C, Caulier MT, Wattel E, Morel P, Wetterwald M, Bauters F, Fenaux P. Hebbar M, et al. Among authors: wetterwald m. Br J Haematol. 1996 Jul;94(1):112-5. doi: 10.1046/j.1365-2141.1996.6322262.x. Br J Haematol. 1996. PMID: 8757517
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.
Moreau P, Attal M, Garban F, Hulin C, Facon T, Marit G, Michallet M, Doyen C, Leyvraz S, Mohty M, Wetterwald M, Mathiot C, Caillot D, Berthou C, Benboubker L, Garderet L, Chaleteix C, Traullé C, Fuzibet JG, Jaubert J, Lamy T, Casassus P, Dib M, Kolb B, Dorvaux V, Grosbois B, Yakoub-Agha I, Harousseau JL, Avet-Loiseau H; SAKK; IFM Group. Moreau P, et al. Among authors: wetterwald m. Leukemia. 2007 Sep;21(9):2020-4. doi: 10.1038/sj.leu.2404832. Epub 2007 Jul 12. Leukemia. 2007. PMID: 17625611
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pégourié B, Kolb B, Stoppa AM, Fuzibet JG, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traullé C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau JL. Moreau P, et al. Among authors: wetterwald m. Blood. 2011 Nov 24;118(22):5752-8; quiz 5982. doi: 10.1182/blood-2011-05-355081. Epub 2011 Aug 17. Blood. 2011. PMID: 21849487 Free article. Clinical Trial.
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat L, Mathiot C, Kolb B, Macro M, Campion L, Wetterwald M, Stoppa AM, Hulin C, Facon T, Attal M, Minvielle S, Harousseau JL. Avet-Loiseau H, et al. Among authors: wetterwald m. J Clin Oncol. 2010 Oct 20;28(30):4630-4. doi: 10.1200/JCO.2010.28.3945. Epub 2010 Jul 19. J Clin Oncol. 2010. PMID: 20644101
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.
Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M, Royer B, Dib M, Voillat L, Bouscary D, Caillot D, Wetterwald M, Pegourie B, Lepeu G, Corront B, Karlin L, Stoppa AM, Fuzibet JG, Delbrel X, Guilhot F, Kolb B, Decaux O, Lamy T, Garderet L, Allangba O, Lifermann F, Anglaret B, Moreau P, Harousseau JL, Facon T. Avet-Loiseau H, et al. Among authors: wetterwald m. J Clin Oncol. 2013 Aug 1;31(22):2806-9. doi: 10.1200/JCO.2012.46.2598. Epub 2013 Jun 24. J Clin Oncol. 2013. PMID: 23796999 Free PMC article.
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, Facon T, Leleu X, Karlin L, Perrot A, Moreau P, Marit G, Stoppa AM, Royer B, Chaleteix C, Tiab M, Araujo C, Lenain P, Macro M, Voog E, Benboubker L, Allangba O, Jourdan E, Orsini-Piocelle F, Brechignac S, Eveillard JR, Belhadj K, Wetterwald M, Pegourie B, Jaccard A, Eisenmann JC, Glaisner S, Mohty M, Hulin C, Loiseau HA, Mathiot C, Attal M. Garderet L, et al. Among authors: wetterwald m. Blood. 2018 Dec 13;132(24):2555-2563. doi: 10.1182/blood-2018-07-863829. Epub 2018 Oct 3. Blood. 2018. PMID: 30282798 Free article. Clinical Trial.
40 results